SFHRAD14
Advise on use and effects of radioactive and non-radioactive medicinal products

Overview

This standard relates to the provision of advice on the use and effects of radioactive and non-radioactive medicinal products. It also includes monitoring and investigation of untoward events arising from the use of radiopharmaceuticals and extraneous factors which may affect the clinical interpretation of scans. It includes the submission of relevant reports when the situation demands.

Users of this standard will need to ensure that practice reflects up to date information and policies.

SFHRAD14

Advise on use and effects of radioactive and non-radioactive medicinal products

Performance criteria

You must be able to:

- P1 in the case of an untoward event, identify products (radioactive and non-radioactive) that do not meet their performance specification
- P2 investigate unusual clinical findings in patient scans to determine any possible relationship to administered radiopharmaceutical
- P3 assess whether unusual clinical findings affect the validity of the scan due to radiopharmaceutical defect or drug interaction
- P4 investigate adverse drug reactions and determine the likely interrelationship between patient symptoms or reaction and administered radiopharmaceutical
- P5 advise on potential drug interactions and interventions that may affect radiopharmaceutical performance or the outcome of an investigation or treatment
- P6 give advice when undesired patient radiation exposure may arise from either misadministration or maladministration of radiopharmaceutical
- P7 submit reports at suitable level of detail and in correct format with appropriate degree of urgency on incidents
- P8 advise on choice and suitability of drug interventions during nuclear medicine procedures where appropriate
- P9 advise on administration of pharmaceuticals for the protection of organs from unwanted radiation exposure where appropriate
- P10 advise on the requirements for cessation of breastfeeding prior to administration of radiopharmaceuticals where appropriate
- P11 correctly interpret and apply relevant standard operating procedures

SFHRAD14

Advise on use and effects of radioactive and non-radioactive medicinal products

Knowledge and understanding

You need to know and understand:

K1 reporting schemes for defects and adverse incidents
K2 expected biodistribution and uptake mechanisms of radiopharmaceuticals
K3 potential and likely causes of abnormal biodistribution
K4 how to recognise an abnormal biodistribution and its implications
K5 side-effects and adverse reactions that can occur following administration of radioactive and non-radioactive medicinal products and their significance
K6 known drug interactions with radiopharmaceuticals
K7 the guidance available on Diagnostic Reference Levels
K8 pharmacology, pharmacokinetics and metabolism of radioactive and non-radioactive medicinal products
K9 sources of information on radioactive and non-radioactive medicinal product specifications and how to access and interpret them
K10 range of relevant standard operating procedures

SFHRAD14

Advise on use and effects of radioactive and non-radioactive medicinal products

Additional Information

External links

This standard links with the following dimension within the NHS Knowledge and Skills Framework (October 2004):

Dimension: HWB10 Products to meet health and wellbeing needs

SFHRAD14

Advise on use and effects of radioactive and non-radioactive medicinal products

Developed by	Skills for Health
Version number	1
Date approved	June 2010
Indicative review date	June 2012
Validity	Current
Status	Original
Originating organisation	Skills for Health
Original URN	RAD14
Relevant occupations	Health, Public Services and Care; Medicine and Dentistry; Healthcare and Related Personal Services
Suite	Radiopharmacy
Key words	radiopharmaceuticals, radiopharmacy